TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities falls 33.6% from a year ago
Other non-current liabilities stood at $12.12M at the end of Q1 FY2026, down 33.6% from a year earlier and down 48.3% from the prior quarter. Over 3 fiscal years it compounded at +298.9% a year.
Context
- Other non-current liabilities amounted to 17.1% of total assets at the end of Q1 FY2026, down 46.7 pp from a year earlier.
- Other non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -33.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 23.42M USD
- Year-over-year change
- +44.3%
- 4-year CAGR
- +154.2%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.42M | +44.3% |
| FY2024 | 2024-12-31 | 16.22M | -54.6% |
| FY2023 | 2023-12-31 | 35.73M | +9583.5% |
| FY2022 | 2022-12-31 | 369K | -34.2% |
| FY2021 | 2021-12-31 | 561K | — |
Other Non-current Liabilities vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's Mar 2026 other non-current liabilities of $12.12M is the 4th highest of the 11 companies compared; the peer median is $540K.
- Its year-over-year change of -33.6% is the 6th highest of 9, against a peer median of +12.6%.
- Other non-current liabilities amounts to 17.1% of total assets for TLSI, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.59M | +19617.9% | +624.8% | 7.0% | |
| Mar 2026 | $28.58M | +5003.9% | -53.3% | 16.3% | |
| Mar 2026 | $21.25M | -67.8% | +590.1% | 32.1% | |
| Mar 2026 | $12.12M | -33.6% | +298.9% | 17.1% | |
| Dec 2025 | $1.16M | +67.3% | -36.6% | 0.7% | |
| Mar 2026 | $818K | -95.7% | +52.7% | 0.9% | |
| Mar 2026 | $262K | -3.0% | -41.6% | 0.1% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $193K | -72.0% | -27.6% | 0.1% |
| Mar 2026 | $92.3K | +28.2% | — | 0.1% | |
| Mar 2026 | $71K | — | — | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TLSI) | $540K | +12.6% | -27.6% | 0.4% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.3M | 9.41M | 11.78M | 8.53M | 20.44M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.36M | 1.56M | 3.55M | 5.09M | 6.56M |
| Inventory | 1.29M | 1.47M | 2.55M | 4.05M | 3.08M |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 35.13M | 17.21M | 20.86M | 20.67M | 32.24M |
| Property, Plant & Equipment (Net) | 1.8M | 3.61M | 3.27M | 2.88M | 2.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 794K | 802K | 0 | 0 | 0 |
| Long-term Investments | 0 | 250K | 0 | 350K | 400K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 115K | 117K | 466K | 73K | 18K |
| Total Non-current Assets | 2.71M | 4.78M | 3.74M | 3.3M | 3.09M |
| Total Assets | 37.84M | 22M | 24.6M | 23.97M | 35.33M |
| Account Payables | 1.3M | 4.95M | 3.39M | 2.27M | 3M |
| Short-term Debt | 0 | 370K | 0 | 0 | 167K |
| Tax Payables | 0 | 0 | 0 | 34K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 104K | 23.57M | 420K | 383K | 8.23M |
| Total Current Liabilities | 6.37M | 32.36M | 14.69M | 10.23M | 11.5M |
| Long-term Debt | 0 | 0 | 0 | 22.08M | 34.27M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 561K | 369K | 35.73M | 16.22M | 23.42M |
| Total Non-current Liabilities | 561K | 1.96M | 36.98M | 39.64M | 57.69M |
| Total Liabilities | 6.93M | 34.32M | 51.66M | 49.87M | 69.19M |
| Common Stock | 11K | 0 | 2K | 3K | 4K |
| Retained Earnings | (136.34M) | (186.36M) | (249.5M) | (279.55M) | (330.58M) |
| Accumulated OCI | 0 | 0 | (0) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 30.9M | (12.32M) | (27.07M) | (25.89M) | (33.86M) |
| Total Debt | 0 | 1.96M | 1.6M | 23.63M | 34.44M |
| Net Debt | (30.3M) | (7.45M) | (10.18M) | 15.1M | 14M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.